Sanofi Pasteur, the vaccines division of Sanofi, has reported that its dengue fever vaccine has reached the primary endpoint in the first of two Phase III pivotal trials of the compound.
written on 29.04.2014
Sanofi Pasteur, the vaccines division of Sanofi, has reported that its dengue fever vaccine has reached the primary endpoint in the first of two Phase III pivotal trials of the compound.
See our Cookie Privacy Policy Here